CCDC141 and breast cancer: In the subsequent investigation on the relationship between the mutations and prognosis, we compared the OS and disease-free survival (DFS) of BC patients who acquired wild-type or mutated CDH9, METTL3PTPRH, and CCDC141 based on the data from the cBioPortal for Cancer Genomics (https://www.cbioportal.org/).